Show simple item record

dc.contributor.authorAnderson, Heather
dc.contributor.authorScarffe, J Howard
dc.contributor.authorSwindell, Ric
dc.contributor.authorCrowther, Derek
dc.date.accessioned2014-12-22T15:38:47Z
dc.date.available2014-12-22T15:38:47Z
dc.date.issued1983-03
dc.identifier.citationSerum beta 2-microglobulin in patients with non-Hodgkin's lymphoma. 1983, 19 (3):327-31 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379
dc.identifier.pmid6190656
dc.identifier.urihttp://hdl.handle.net/10541/337549
dc.description.abstractEighty-one patients with non-Hodgkin's lymphoma had serum beta 2-microglobulin (beta 2M) estimated at presentation. A significant association was found between beta 2M levels and stage of disease (P less than 0.001), presence of hepatomegaly (P less than 0.001) and bone marrow involvement (P less than 0.05). No association was found between the level of beta 2M and histological group, presence of splenomegaly, lymph-node masses greater than 5 cm in diameter, lymphocyte count or the presence of systemic B symptoms. Pretreatment levels of beta 2M did not help predict response to treatment and achievement of a complete remission, the length of remission obtained or survival.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer & clinical oncologyen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBeta-Globulins
dc.subject.meshBone Marrow
dc.subject.meshHepatomegaly
dc.subject.meshHumans
dc.subject.meshLeukocyte Count
dc.subject.meshLymphocytes
dc.subject.meshLymphoma
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshPrognosis
dc.subject.meshbeta 2-Microglobulin
dc.titleSerum beta 2-microglobulin in patients with non-Hodgkin's lymphoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester M20 9BXen
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen
html.description.abstractEighty-one patients with non-Hodgkin's lymphoma had serum beta 2-microglobulin (beta 2M) estimated at presentation. A significant association was found between beta 2M levels and stage of disease (P less than 0.001), presence of hepatomegaly (P less than 0.001) and bone marrow involvement (P less than 0.05). No association was found between the level of beta 2M and histological group, presence of splenomegaly, lymph-node masses greater than 5 cm in diameter, lymphocyte count or the presence of systemic B symptoms. Pretreatment levels of beta 2M did not help predict response to treatment and achievement of a complete remission, the length of remission obtained or survival.


This item appears in the following Collection(s)

Show simple item record